Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...
US Dollar South African Rand, Nasdaq 100, S&P 500, Eli Lilly and Company. Read Vestact 's latest article on Investing.com South Africa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback